siRNA-mediated silencing of Wnt5a regulates inflammatory responses in atherosclerosis through the MAPK/NF-κB pathways

Yang,Lei; Chu,Yingjie; Wang,Yuhang; Zhao,Xiangmei; Xu,Wenke; Zhang,Peirong; Liu,Xiaoyu; Dong,Shujuan; He,Wenqi; Gao,Chuanyu

doi:10.3892/ijmm.2014.1860

siRNA-mediated silencing of Wnt5a regulates inflammatory responses in atherosclerosis through the MAPK/NF-κB pathways

Authors:
- Lei Yang
- Yingjie Chu
- Yuhang Wang
- Xiangmei Zhao
- Wenke Xu
- Peirong Zhang
- Xiaoyu Liu
- Shujuan Dong
- Wenqi He
- Chuanyu Gao
View Affiliations

Affiliations: Department of Emergency Medicine, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China, Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China
Published online on: July 22, 2014 https://doi.org/10.3892/ijmm.2014.1860
Pages: 1147-1152

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that the aberrant expression of Wnt5a occurs in atherosclerotic lesions. However, the precise role of Wnt5a in the pathogenesis of atherosclerosis remains largely unknown. The present study was undertaken to determine whether the RNA interference of Wnt5a in vivo by adenovirus (Ad)-mediated small interfering RNA (siRNA) transfection is capable of inhibiting the progression of atherosclerosis. Recombinant adenovirus carrying siRNA targeting Wnt5a (Ad-Wnt5a siRNA) was designed. Male apolipoprotein E-deficient (ApoE-/-) mice were fed a high-fat diet to induce the pathogenesis of atherosclerosis. Mice were randomly divided into 3 groups (n=15 in each group): the mock group, which received treatment with phosphate-buffered saline (PBS); the Ad-NC group, which received treatment with Ad-non-specific siRNA; and the Ad-Wnt5a siRNA group, which received treatment with Ad-Wnt5a siRNA. Treatment with Ad-Wnt5a siRNA markedly inhibited the mRNA and protein expression of Wnt5a in the aortic tissues. The knockdown of Wnt5a had no significant effect on blood lipid levels, but it suppressed atherosclerotic development and increased plaque stability, which was determined by hematoxylin and eosin staining, picrosirius red staining and Oil Red O staining. Furthermore, the mRNA and protein expression of inflammatory cytokines, including monocyte chemotactic protein-1 (MCP-1), cyclooxygenase-2 (COX-2), matrix metalloproteinase (MMP)-2 and MMP-9 was significantly downregulated in the Ad-Wnt5a siRNA group. In addition, the knockdown of Wnt5a inhibited the nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways. These results demonstrate that Ad-mediated Wnt5a silencing in vivo attenuates the development of atherosclerotic disease by reducing inflammatory mediators involved in the MAPK/NF-κB pathways.

View Figures

View References

1	Glass CK and Witztum JL: Atherosclerosis. the road ahead. Cell. 104:503–516. 2001. View Article : Google Scholar : PubMed/NCBI
2	Li AC and Glass CK: The macrophage foam cell as a target for therapeutic intervention. Nat Med. 8:1235–1242. 2002. View Article : Google Scholar : PubMed/NCBI
3	Kikuchi A, Yamamoto H, Sato A and Matsumoto S: Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf). 204:17–33. 2012. View Article : Google Scholar : PubMed/NCBI
4	Sen M, Lauterbach K, El-Gabalawy H, et al: Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci USA. 97:2791–2796. 2000. View Article : Google Scholar : PubMed/NCBI
5	Christman MA II, Goetz DJ, Dickerson E, et al: Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol. 294:H2864–H2870. 2008. View Article : Google Scholar : PubMed/NCBI
6	Reischl J, Schwenke S, Beekman JM, et al: Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol. 127:163–169. 2007. View Article : Google Scholar : PubMed/NCBI
7	Pereira C, Schaer DJ, Bachli EB, Kurrer MO and Schoedon G: Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 28:504–510. 2008. View Article : Google Scholar
8	Halleskog C, Dijksterhuis JP, Kilander MB, et al: Heterotrimeric G protein-dependent WNT-5A signaling to ERK1/2 mediates distinct aspects of microglia proinflammatory transformation. J Neuroinflammation. 9:1112012. View Article : Google Scholar
9	Kim J, Kim J, Kim DW, Ha Y, et al: Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol. 185:1274–1282. 2010. View Article : Google Scholar : PubMed/NCBI
10	Jung YS, Lee HY, Kim SD, et al: Wnt5a stimulates chemotactic migration and chemokine production in human neutrophils. Exp Mol Med. 45:e272013. View Article : Google Scholar : PubMed/NCBI
11	Malgor R, Bhatt PM, Connolly BA, et al: Wnt5a, TLR2 and TLR4 are elevated in advanced human atherosclerotic lesions. Inflamm Res. 63:277–285. 2014. View Article : Google Scholar : PubMed/NCBI
12	Yan X, Baxter RC, Perbal B and Firth SM: The aminoterminal insulin-like growth factor (IGF) binding domain of IGF binding protein-3 cannot be functionally substituted by the structurally homologous domain of CCN3. Endocrinology. 147:5268–5274. 2006. View Article : Google Scholar
13	Libby P, Ridker PM and Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 54:2129–2138. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kutuk O and Basaga H: Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med. 9:549–557. 2003. View Article : Google Scholar : PubMed/NCBI
15	Chan ED and Riches DW: IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol. 280:C441–C450. 2001.PubMed/NCBI
16	Schönbeck U, Sukhova GK, Graber P, Coulter S and Libby P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 155:1281–1291. 1999.PubMed/NCBI
17	Burleigh ME, Babaev VR, Oates JA, et al: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 105:1816–1823. 2002. View Article : Google Scholar : PubMed/NCBI
18	Burleigh ME, Babaev VR, Yancey PG, et al: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 39:443–452. 2005. View Article : Google Scholar : PubMed/NCBI
19	Gosling J, Slaymaker S, Gu L, et al: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 103:773–778. 1999. View Article : Google Scholar : PubMed/NCBI
20	Falk E: Pathogenesis of atherosclerosis. J Am Coll Cardiol. 47(Suppl 8): C7–C12. 2006. View Article : Google Scholar
21	Davies MJ: The pathophysiology of acute coronary syndromes. Heart. 83:361–366. 2000. View Article : Google Scholar : PubMed/NCBI
22	Schaar JA, Muller JE, Falk E, et al: Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J. 25:1077–1082. 2004.PubMed/NCBI
23	Ylä-Herttuala S, Bentzon JF, Daemen M, et al: Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost. 106:1–19. 2011.PubMed/NCBI
24	Naghavi M, Libby P, Falk E, et al: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 108:1664–1672. 2003. View Article : Google Scholar
25	Newby AC: Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 28:2108–2114. 2008. View Article : Google Scholar : PubMed/NCBI
26	Bond M, Fabunmi RP, Baker AH and Newby AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 435:29–34. 1998. View Article : Google Scholar
27	Wang J, Zhang R, Xu Y, et al: Genistein inhibits the development of atherosclerosis via inhibiting NF-kappaB and VCAM-1 expression in LDLR knockout mice. Can J Physiol Pharmacol. 86:777–784. 2008. View Article : Google Scholar : PubMed/NCBI
28	Muslin AJ: MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond). 115:203–218. 2008. View Article : Google Scholar : PubMed/NCBI